Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
Marinus Pharmaceuticals (Nasdaq: MRNS), a company focused on developing therapeutics for seizure disorders, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 10:20 a.m. ET.
Investors and interested parties can access the event through a live webcast link available on the Investors and Media page of Marinus' website. For those unable to attend live, a replay of the webcast will be made available approximately two hours after the event concludes and will remain accessible for up to 90 days.
Marinus Pharmaceuticals (Nasdaq: MRNS), un'azienda focalizzata nello sviluppo di terapie per disturbi convulsivi, ha annunciato la sua partecipazione alla Conferenza Globale sulla Salute Cantor 2024. Il management dell'azienda parteciperà a un incontro informale giovedì 19 settembre 2024, alle 10:20 ora ET.
Gli investitori e le parti interessate possono accedere all'evento tramite un link per webcast dal vivo disponibile nella pagina Investitori e Media del sito web di Marinus. Per coloro che non possono partecipare dal vivo, sarà disponibile una registrazione del webcast circa due ore dopo la conclusione dell'evento e rimarrà accessibile per un massimo di 90 giorni.
Marinus Pharmaceuticals (Nasdaq: MRNS), una empresa centrada en el desarrollo de terapias para trastornos convulsivos, ha anunciado su participación en la Conferencia Global de Salud de Cantor 2024. La dirección de la empresa participará en un chat informal el jueves 19 de septiembre de 2024, a las 10:20 a.m. ET.
Los inversores y partes interesadas pueden acceder al evento a través de un enlace de transmisión en vivo disponible en la página de Inversores y Medios del sitio web de Marinus. Para aquellos que no puedan asistir en vivo, se hará disponible una repetición de la transmisión aproximadamente dos horas después de que concluya el evento y estará accesible durante un máximo de 90 días.
Marinus Pharmaceuticals (Nasdaq: MRNS)는 발작 장애 치료제를 개발하는 데 집중하는 회사로, 2024 Cantor Global Healthcare Conference에 참여한다고 발표했습니다. 회사 경영진은 2024년 9월 19일 목요일, 오전 10:20 ET에 파이어사이드 채팅에 참여합니다.
투자자 및 관심 있는 당사자는 Marinus 웹사이트의 투자자 및 미디어 페이지에서 제공되는 라이브 웹캐스트 링크를 통해 해당 이벤트에 접근할 수 있습니다. 라이브로 참석할 수 없는 분들을 위해, 이벤트 종료 약 두 시간 후에 재생 된 웹캐스트가 제공되며 최대 90일 동안 접근할 수 있습니다.
Marinus Pharmaceuticals (Nasdaq: MRNS), une entreprise axée sur le développement de thérapies pour les troubles de la convulsion, a annoncé sa participation à la Conférence mondiale sur la santé de Cantor 2024. La direction de l'entreprise participera à une discussion informelle le jeudi 19 septembre 2024, à 10h20 ET.
Les investisseurs et les parties intéressées peuvent accéder à l'événement via un lien de webcast en direct disponible sur la page Investisseurs et Médias du site Web de Marinus. Pour ceux qui ne peuvent pas assister en direct, une retransmission du webcast sera disponible environ deux heures après la fin de l'événement et restera accessible pendant un maximum de 90 jours.
Marinus Pharmaceuticals (Nasdaq: MRNS), ein Unternehmen, das sich auf die Entwicklung von Therapeutika für Krampferkrankungen konzentriert, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference bekannt gegeben. Das Management des Unternehmens wird am Donnerstag, den 19. September 2024, um 10:20 Uhr ET an einem Feuerplatzgespräch teilnehmen.
Investoren und Interessierte können die Veranstaltung über einen Live-Webcast-Link, der auf der Seite für Investoren und Medien der Marinus-Website verfügbar ist, verfolgen. Für diejenigen, die nicht live teilnehmen können, wird etwa zwei Stunden nach Ende der Veranstaltung eine Wiedergabe des Webcasts zur Verfügung stehen und bis zu 90 Tage zugänglich sein.
- None.
- None.
A link to the event can be accessed on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910315715/en/
Investors
Sonya Weigle
Chief People and Investor Relations Officer
Marinus Pharmaceuticals, Inc.
sweigle@marinuspharma.com
Media
Molly Cameron
Director, Corporate Communications & Investor Relations
Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Source: Marinus Pharmaceuticals
FAQ
When is Marinus Pharmaceuticals (MRNS) presenting at the 2024 Cantor Global Healthcare Conference?
How can I access Marinus Pharmaceuticals' (MRNS) presentation at the 2024 Cantor Global Healthcare Conference?
Will there be a replay available of Marinus Pharmaceuticals' (MRNS) presentation at the 2024 Cantor Global Healthcare Conference?
What is the focus of Marinus Pharmaceuticals (MRNS) as mentioned in the press release?
